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Abstract
The inhibition properties and target sites of monoclonal antibodies (mAbs) Elec403, Elec408 and Elec410, generated
against Electrophorus electricus acetylcholinesterase (AChE), have been defined previously using biochemical and
mutagenesis approaches. Elec403 and Elec410, which bind competitively with each other and with the peptidic toxin
inhibitor fasciculin, are directed toward distinctive albeit overlapping epitopes located at the AChE peripheral anionic
site, which surrounds the entrance of the active site gorge. Elec408, which is not competitive with the other two mAbs
nor fasciculin, targets a second epitope located in the backdoor region, distant from the gorge entrance. To
characterize the molecular determinants dictating their binding site specificity, we cloned and sequenced the mAbs;
generated antigen-binding fragments (Fab) retaining the parental inhibition properties; and explored their structure-
function relationships using complementary x-ray crystallography, homology modeling and flexible docking
approaches. Hypermutation of one Elec403 complementarity-determining region suggests occurrence of antigen-
driven selection towards recognition of the AChE peripheral site. Comparative analysis of the 1.9Å-resolution
structure of Fab408 and of theoretical models of its Fab403 and Fab410 congeners evidences distinctive surface
topographies and anisotropic repartitions of charges, consistent with their respective target sites and inhibition
properties. Finally, a validated, data-driven docking model of the Fab403-AChE complex suggests a mode of binding
at the PAS that fully correlates with the functional data. This comprehensive study documents the molecular
peculiarities of Fab403 and Fab410, as the largest peptidic inhibitors directed towards the peripheral site, and those
of Fab408, as the first inhibitor directed toward the backdoor region of an AChE and a unique template for the design
of new, specific modulators of AChE catalysis.
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Introduction
Acetylcholinesterase (AChE, EC 3.1.1.7) terminates
cholinergic neurotransmission by rapidly catalyzing hydrolysis
of the neurotransmitter, acetylcholine, at neuronal and
neuromuscular synapses [1-3]. The active site of AChE, that
contains the Glu/His/Ser catalytic triad and binds competitive
reversible or irreversible inhibitors, is located at the center of
the subunit at the end of a deep and narrow gorge [4]. At the
enzyme surface and entrance of the active site gorge, the
peripheral anionic site (PAS) encompasses overlapping binding
loci for a range of reversible inhibitors and activators [5], and
acetylcholine in certain conditions [6-8]. Inhibitor binding at the
PAS appears to limit the catalytic rate by a combination of
steric and electrostatic blockade of ligand trafficking through
the gorge and by altering the active center conformation [9-12].
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e77226
The molecular and electrostatics topographies and
conformational flexibility of the PAS have been characterized
thoroughly, but the mechanisms of its allosteric functioning to
alter the active site geometry remain unclear [13-17].
Non-competitive inhibitors that bind the PAS of AChE include
small organic cations such as propidium or gallamine [5,15,18],
one quaternary group of bisquaternary inhibitors that fully
occupy the gorge and bind both the active center and the PAS,
such as decamethonium and BW284C51 [18-21], and the
larger cation and first peptidic AChE inhibitor to be
characterized, the three-fingered snake toxin fasciculin
[13,22-26]. Crystal structures of fasciculin 2 (Fas2)-AChE
complexes revealed the large surface area and multiple
electrostatic and hydrophobic anchoring points solicited by the
bound toxin at the PAS, along with apparent occlusion of the
AChE gorge by the Fas2 central finger, loop II, all features
being consistent with the nano- to picomolar affinity of the
complex [13,26]. However, the structures failed to document
the molecular or dynamical features responsible for the ~1%
residual acetylcholine hydrolysis activity of the Fas2-AChE
complex observed in solution [14,23-25]. Compatibility between
the solution and structural data was suggested to require either
conformational flexibility of the complex, creating a gap
between the enzyme surface and the bound fasciculin, or
opening of a backdoor, distinct from the gorge entrance, and
whose transient enlargement would permit fractional substrate/
product trafficking in the complex [13]. Shutter-like motion of
the aromatic side chain of either residue Trp84 or residue
Tyr442 (Torpedo californica AChE (TcAChE) numbering),
which make thin walls between the active site pocket and the
outside solvent in the putative backdoor region (BDR), have
been visualized by molecular dynamics simulations [27-29] and
x-ray crystallography [30,31], respectively.
In addition to fasciculins, various polyclonal and monoclonal
antibodies (mAbs) have been shown to inhibit AChE by binding
to “modulatory” sites on the enzyme surface (cf. References
[S1-S15] in File S1). The target sites of three of them, raised
against the Electrophorus electricus AChE (EeAChE) subunit
and named Elec403, Elec408 and Elec410, were identified
using complementary binding, inhibition and mutagenesis
approaches [32,33]. In fact, Elec403 and Elec410 bind
EeAChE competitively to each other and to Fas2, while only
Elec403 also binds competitively with the organic PAS ligands
propidium, decamethonium and BW284C51, and the substrate
when in excess [32]. The Elec403- and Elec410-EeAChE
complexes display residual activities of a few percent (i.e.,
slightly higher than that of the Fas2-AChE complex), while the
Elec408-EeAChE complex displays one order of magnitude
greater residual activity [32]. Inhibition of the residual activity of
the Elec403 complex by the positively charged
organophosphate inhibitor, echothiophate, and the transition
state analog, TMTFA, occurs at lower rates than inhibition of
the unbound enzyme, while for the Elec410 complex only
inhibition by TMTFA is reduced, and for the Elec408 complex
both inhibition rates are unaltered [33]. These features, along
with delineation of the respective binding surfaces using
mutagenesis of EeAChE [33], led to conclude that Elec403 and
Elec410 are directed toward distinct but overlapping epitopes
located at the enzyme PAS, whereas Elec408 targets a distinct
regulatory site located in the BDR, and triggers a new inhibition
mechanism. Finally, Elec403 and Elec408 are specific to
EeAChE while Elec410 also inhibits, although to lesser
extends, the venom enzymes from the snakes Bungarus
fasciatus (BfAChE) and Ophiophagus Hannah, with IC50 values
of ~1 nM and ~50 nM, respectively [32,34]. Hence, these three
mAbs represent new promising peptidic tools to study allosteric
regulation of AChE catalysis through surface binding sites.
To characterize the molecular determinants of these
inhibitory “Elec” mAbs and provide structure-function
relationships arguments into their binding site selectivity and
mode of action, we have cloned and sequenced the three of
them; generated, purified, characterized their antigen-binding
fragments (Fabs); solved a crystal structure of Fab408 and
designed homology models of Fab403 and Fab410; and used
and validated a flexible docking approach to generate a model
of a Fab403-EeAChE complex that tightly correlates with the
available functional data. This complementary study
documents, at the atomic level, the molecular peculiarities of
new tools for exploring allosteric modulation of AChE catalysis:
Fab403 and Fab410, as the largest peptidic ligands directed
towards the PAS, and Fab408, as the first inhibitor directed
toward the BDR.
Materials and Methods
Cloning and sequencing of the Fabs
The three mAbs were produced as IgG1,κ from murine
hybridomas [32]. The cDNAs corresponding to the variable
regions in the heavy and light chains (VH and VL) were
obtained using the specific Cγ1 primer (5′-AGG GGC CAG
TGG ATA GAC-3′), complementary to the sequence encoding
residues 141–147 of the CH region of the γ1 chain, and the
RevCκSal 1 primer (5′-GCT GAT GCT GCA CCA ACT AWG
TCC ATC TTC-C3′), complementary to the sequence encoding
residues 209–214 of the CL region of the κ chain [35]. The
mixture containing 7 μl of RNA (~5 μg), 1 μl of dNTP (final
concentration, 500 μM), 1 μl of primers (final concentration of
each, 0.2 μM), and 7.5 μl of RNase-free water was heated at
70°C for 10 min. Primer annealing and reverse transcription
were carried out in the presence of 1 μl of AMV reverse
transcriptase (1 U/μl) and 0.5 μl of RNase inhibitor (1 U/μl) at
42 °C for 50 min. The final 20 μl sample containing the cDNA
products was stored at −20°C until use. PCR amplification of
the VH and VL sequences used primer mixtures as described
[36]. In brief, the final 50 μl sample, containing 5 μl of first-
strand cDNA, 0.2 μM of back and forward primers, 200 μM of
dNTP, 1.5-5.5 mM of MgCl2, and 5 μl of 10x buffer, was heated
at 92°C for 3 min, and then subjected to 25 cycles (92°C for 1
min, 72°C for 30 s, 72°C for 1 min) in presence of 1 unit of
DyNAzyme™ EXT DNA Polymerase (Finnzymes, Oy, Finland).
The reaction was stopped with a 72°C step for 7 min. One-
tenth of each PCR reaction was analyzed on a 2% agarose gel
stained with ethidium bromide. The sequences of the PCR
products were verified (Eurofins MWG Operon), and analyzed
using the IMGT/V-QUEST tool [37,38]. The nucleotide
sequences have been deposited with The EMBL Nucleotide
Structure of Inhibitory Anti-AChE Antibodies
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Sequence Database, accession codes HE984312 and
HE984313, HE984314 and HE984315, and HE984316 and
HE984317 for the VL and VH domains of Elec403, Elec408
and Elec410, respectively.
The Fab complementary determining region (CDR)
boundaries were defined according to the IMGT standards
(Figure S1 in File S1). However, to avoid virtual gaps in the
structure coordinates and inconsistencies related to definition
of β-strands, the consecutive numbering of residues and Greek
letter labeling of β-strands and α-helices will be used herein
(Figure 1).
Biochemical and functional analyses
Protein purification and preparation, biochemical and
functional analyses, and N-linked carbohydrate removal used
standard procedures as described as Supplemental
Experimental Procedures in File S1.
Solution and refinement of the Fab408 structure
The procedures for crystallization of Fab408 and data
collection are described as Supplemental Experimental
Procedures in File S1. Initial phases were obtained by
molecular replacement with the AMoRe program package [39]
using, as search models, the structures of the variable and
constant domains of Fv Huh52-Aa (accession code 1FGV) and
FabE8 (accession code 1WEJ), respectively. This procedure
yielded a correlation coefficient of 53.9% and an R-factor value
of 39.1% in the 10-4 Å resolution range. Automatic building of
the initial model with ARP/wARP yielded a virtually complete
model consisting of a single Fab408 molecule [40]. The model
was improved by manual adjustment with the graphics program
COOT [41] and was refined with Refmac [42] including TLS
refinement with each variable and constant domain defining a
TLS group. Data collection and refinement statistics are
summarized in Table S1 in File S1.
The final structure of Fab408 comprises 213 and 224
residues for the L and H chains, respectively, and 208 water
molecules. CDR-L1 adopts a conformation similar to the
canonical structural class 2 [43,44], CDR-L2, CDR-L3 and
CDR-H1 belong to class 1, CDR-H2 belongs to class 2 and
CDR-H3 does not belong to an identified class. High
temperature factors and weak electron densities are associated
with segments Glu42-Lys43, Thr55-Thr58, Lys65-Lys67,
Leu105-Trp109 and Gly138-Ser145 in the H chain and
residues Asn212-Ala213 in the L chain (Figure 1).
Stereochemistry of the structure was analyzed with
MOLPROBITY [45]; only L chain residue Ala51 was found in
the disallowed regions of the Ramachandran plot. Six cis-Pro
residues are found at positions 158, 160 and 200 in the CH
domain and at positions 8 and 95 in the VL domain and 141 in
the CL domain; all six positions are conserved in the three
Fabs (Figure 1). The atomic coordinates and structure factors
of Fab408 have been deposited with the RCSB Data Bank,
accession code 2YMX.
Theoretical modeling of Fab403 and Fab410 and of a
Fab403-EeAChE complex
The Fab403 and Fab410 models were built using
MODELLER [46] and, as a template, the structure of the Fab
fragment of the virus-neutralizing mAb SD6 (accession code,
1QGC, 77-80% identity), selected using the TM-score from the
HHpred server [47]. The average root mean square deviation
values between the Fab403 and Fab410 models and the
template are ~0.34 Å and ~0.25 Å, respectively, for 212/213 Cα
atoms. Between the three Fabs the values are in the 1-2 Å
range for 212 Cα atoms, with the highest deviations observed
Figure 1.  Sequences and numbering of the three anti-EeAChE Fabs.  The light (L, top) and heavy (H, bottom) chains are
displayed. The residue numbering and secondary structure elements displayed above the alignment are those of Fab408.
Conserved residues are shown on a black background and non-conserved residues on a white background. The CDRs, defined
according to http://www.bioinf.org.uk/abs/ (cf. Figure S1 in File S1), are highlighted as grey boxes and labeled.
doi: 10.1371/journal.pone.0077226.g001
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for the solvent-exposed CDR-H2 and CDR-H3 of Fab403 and
Fab410. In the Fab403 model, CDR-H1, CDR-H2, CDR-L1,
CDR-L2 belong to structural classes 1, 2, 1, 1, while CDR-H3
and CDR-L3 do not belong to an identified class; the side
chains of CDR-H1 residues Thr28, Thr30-Trp33; CDR-H2
residues Tyr52, His54, Thr55, Thr57; CDR-H3 residues Arg98,
Asp100-Trp103, Asp106; CDR-L1 residues Ser26-Ser28,
Arg30, Tyr31; CDR-L2 residues Ser51 and Asn52; and CDR-
L3 residues Arg90, Ser91, Tyr93, point towards the solvent. In
the Fab410 model, CDR-L1, CDR-L2, CDR-L3, and CDR-H1
belong to class 1 and CDR-H2 to class 4; CDR-H3 does not
belong to an identified class; the side chains of CDR-L1
residues Ser27, Ser28, Ser30, Tyr31; CDR-L2 residues Arg49,
Ser51; CDR-L3 residues Tyr90, Asn91, His93; CDR-H1
residues Thr28, Asn30-Tyr32; CDR-H2 residues Arg52, Lys54,
Lys57, Tyr58; and CDR-H3 residues Arg100, Ser103-Ser108,
point towards the solvent.
A model of the EeAChE subunit, devoid of the EeAChE-
specific insert Ile418-Gln446 and C-terminal T peptide Ala576-
Leu610 (Figure S2 in File S1) [48], was designed using the
structure of a TcAChE subunit (accession code 1EA5) as a
template and the same procedure as above described for the
Fab models. The average root mean square deviation value
between the model and template is 0.18 Å for 532 Cα residues.
The model of the Fab403-EeAChE complex was generated
by flexible docking using HADDOCK 2.1 [49] and default
parameters and, as possible interfacial active residues, nine
residues of the Fab403 CDRs (four from the H chain and five
from the L chain) and the three interacting Ser75, Gln279 and
Leu282 residues of EeAChE [33]. Neighboring solvent-
accessible residues (four for Fab403 and four for EeAChE,
including the potentially N-glycosylated Asn345) suitably
positioned for being indirectly involved in the binding, were
defined as passive residues. For each run, the top 200
complexes generated after rigid body energy minimization were
subjected to flexible simulated annealing in torsion angle space
and to flexible water refinement in Cartesian space, and the
three energetically best models scored by HADDOCK were
comparatively analyzed.
The models of the Fas2-mouse AChE (mAChE) and Fas2-
EeAChE complexes were generated using a similar approach
and a randomly oriented Fas2 molecule relative to the mAChE
(accession code, 1KU6) and EeAChE subunits. Similar
ambiguous interaction restraints were defined from each
partner corresponding to five and four active residues from the
interfacial regions of mAChE/EeAChE (PAS region) and Fas2
(loop II), respectively, associated to three surrounding passive
residues from each partner.
Structural analysis and comparisons
Electrostatic surface potentials of the three Fabs and of
EeAChE, TcAChE, and mAChE were calculated using APBS
[50] with the PyMOL APBS tools. The molecular surface area
buried to a 1.4 Å radius probe at the Fab403-EeAChE complex
interface was calculated using Areaimol [51]. Structural
superimposition of this complex with the Fas2-mAChE
(accession code 1KU6 [13]), BW284C51-TcAChE (1E3Q [21]),
decamethonium-TcAChE (1ACL [20]), propidium-mAChE
(1N5R [15]), and ACh-mAChE (Ser203Ala mutant) complexes
(2HA4 [7]), based on the respective AChE subunits, used
COOT (root mean square deviation values, 0.89-0.98 Å for
521-526 Cα atoms). Figures were generated using PyMOL
[52].
Results and Discussion
Cloning and sequencing of mAbs Elec403, Elec408 and
Elec410
Analysis of several independent clones resulted in
unambiguous consensus nucleotide sequences for the VL and
VH domains of each of the three mAbs (Figure 1A).
Homogeneity in the results validated the cloning strategy, while
the amino acid sequences of the Elec408 VL and VH domains
were further validated during refinement of the crystal structure.
All VL and VH regions are associated with a germline V region
allele, and it is likely that the observed mutations were induced
by the affinity maturation process associated with the repeated
immunization protocols used to generate the mAbs [32]. The
sequences of these antibodies reveal an abundance of Tyr
residues in the CDRs that, combined with flexible Ser/Gly
residues, reflect functional paratopes capable of mediating
antigen recognition with high affinity and specificity [53]. The
observed level of mutation throughout the three mAbs is
generally classical [54], except for Elec403 whose CDR-H2 and
subsequent two residues are entirely modified (Figure S1A in
File S1). In fact, close homology of the new sequence with that
of Fas2 loop I, which binds at the periphery of the gorge
entrance in the Fas2-AChE complex [13,26], is intriguing. Even
though similar sequences, either straight or reverse, can be
found in unrelated proteins, hypermutation of this CDR into this
sequence may denote particular adaptation pressure toward
the EeAChE PAS.
Physicochemical and functional characterization of the
Fabs
Fab403, Fab408 and Fab410 were generated from the
parental IgGs by cleavage of the H chains, purified using
standard procedures and analyzed using complementary
techniques (Figure 2AB; Table 1). MALDI-TOF mass
spectrometry and SDS-PAGE analyses showed proper
molecular masses, of ca. 50 kDa, and high homogeneity apart
from minor scattering and traces of unlinked H and L chains.
Native-PAGE analysis revealed well-defined bands indicative
of Fab isoforms differing in their net charges, along with greater
average mobility towards the anode for Fab408 compared to
Fab403 and Fab410. Isoelectric focusing analysis showed
similar migration patterns to native-PAGE and led to define
average pI values of ~9.0 for Fab403, ~7.0 for Fab408 and
~8.5 for Fab410, similar to the theoretical values calculated
from the sequences. These values are also consistent with
binding of Elec403 and Elec410, but not Elec408, to the PAS of
EeAChE, as do the cationic inhibitors Fas2, propidium and
gallamine [15,32,33].
Functional analysis of the three Fabs addressed their
capacity to bind to and inhibit the EeAChE tetramer
enzymatically processed from the natural asymmetric
Structure of Inhibitory Anti-AChE Antibodies
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dodecamer [32,55] (cf. Reference [S5] and Supplemental
Experimental Procedures in File S1). For each Fab, all charge
isoforms were found to bind EeAChE equally, as assessed by
a native-PAGE mobility shift assay (data not shown). As well,
both native-PAGE mobility shift and AChE inhibition assays
assessed for mutually exclusive binding of Fab403 and Fab410
to EeAChE, while either could bind simultaneously with Fab408
to form stable ternary complexes of two different Fabs per
EeAChE subunit (data not shown). Upon equilibrium binding
analysis, IC50 values in the 10-10-10-9 M range, and values of
residual activity at saturating Fab concentrations in the 4-7%
range for Fab403 and Fab410 and of ~30% for Fab408, were
obtained (Figure 2C; Table 1), similar to the values reported for
the parental IgGs [32]. Kinetic analyses revealed 2-fold slower
association (ki constant) and ~2-fold faster dissociation (k-i) of
Fab403 compared with Fab410 (Table 1), suggesting different
levels of conformational adaptation of their combining sites to
their binding subsites at the EeAChE PAS. In turn, the Fab408
association rate, one order of magnitude greater than those of
its two congeners, and its dissociation rate, 5-fold and 2-fold
lower respectively, may denote genuine complementarity of the
Fab408 combining site with its binding surface in the BDR. In
all three cases the calculated dissociation constants (Ki) match
the IC50 values. The reverse ranking in the Ki values, which
reflect the Fab403/Fab410 and Fab408 capacities to bind the
EeAChE surface, relative to the residual activities, which reflect
the Fab capacities to inhibit the EeAChE activity, is consistent
with the PAS and the BDR triggering distinctive mechanisms
for allosteric inhibition of catalysis.
Table 1. Biochemical and functional parameters for the
purified Fabs and their EeAChE complexes.
Fab Fab403 Fab408 Fab410
Theoretical mass (kDa) a 46.8 47.5 48.5
Monoisotopic mass (kDa) b 47.5 ± 1.3 48.7 ± 1.2 48.7 ± 1.4
Theoretical pI a 8.6 6.3 8.1
Observed pI c 9.0 7.0 8.5
Enzyme EeAChE EeAChE EeAChE
Binding site PAS BDR PAS
IC50 IgG (nM) d,f (1) (0.04) (0.04)
IC50 Fab (nM) d 5.1 ± 2.38 0.14 ± 0.06 0.53 ± 0.24
ki Fab (nM-1min-1) 0.016 ± 0.023e 0.255 ± 0.061d 0.029 ± 0.015d
k-i Fab (min-1) 0.075 ± 0.019e 0.015 ± 0.009d 0.033 ± 0.004e
Calculated Ki Fab (nM) 4.64 ± 0.42 0.06 ± 0.07 1.13 ± 0.02
Residual activity Fab (%) d 6.6 ± 1.9 30.0 ± 2.6 4.7 ± 1.0
Residual activity IgG (%) d,f (3) (30) (6)
a. Calculated from http://web.expasy.org/protparam/
b. By MALDI-TOF mass spectrometry
c. By isoelectric focusing
d. Values shown as means ± SD (n > 2)
e. Values shown as averages ± the variation (n = 2)
f. Values in parentheses are from [32]
nd, not determined
doi: 10.1371/journal.pone.0077226.t001
Effect of N-linked carbohydrate removal on EeAChE
activity and Fab binding
There are six consensus sites for N-glycosylation at the
surface of the EeAChE subunit (Figure S2 in File S1).
PNGaseF treatment of EeAChE in native conditions followed
by SDS-PAGE analysis resulted in lower apparent molecular
masses for each of the three bands, of ca. 80, 50 and 30 kDa,
typically observed for the reduced subunit (cf. Figure 1 in [55])
(data not shown). The positional shift was identical to that
observed with a fully deglycosylated EeAChE control, thereby
assessing for optimal removal of all PNGase-sensible glycan
chains despite the milder conditions. In contrast, native-PAGE
showed no significant migration difference between the native
and deglycosylated enzymes (data not shown), suggesting that
a loss of negative charges, possibly carried out by sialylated
glycan chains [56], was associated with the loss in mass.
Compared with native EeAChE, the specific activity of
deglycosylated EeAChE was found to be virtually unaltered
(data not shown), but inhibition of deglycosylated EeAChE by
Fab403 led to near one order of magnitude lower IC50 value,
with no change in the residual activity recorded at high Fab
concentration (Figure 2C). The same observation was made
with Fab409, prepared from IgG409 that was initially described
as “similar in [ ] many respects” to IgG403 (data not shown)
[32]. The gain in affinity suggests that one or several N-glycan
chains proximal to the Fab403 (or Fab409) binding site in the
PAS region hinder(s) proper recognition of the original epitope,
although all three Fabs were generated against naturally
glycosylated EeAChE [32]. In contrast, inhibition of the
deglycosylated enzyme by Fab408 and Fab410 showed no
difference in the IC50 and residual activity values. This is
consistent with only partially overlapping binding loci for
Fab403 and Fab410 at the PAS, respectively close to and
remote from the hindering N-glycan(s), and with a fully
distinctive binding site for Fab408 in the BDR.
TcAChE and human, bovine and rat AChEs, which share ca.
60% sequence identity with EeAChE and bear three to four N-
glycosylation sites, are insensitive to the Elec mAbs [32,33].
Butyrylcholinesterase from human plasma (HuBChE) shares
ca. 50% sequence identity with EeAChE and bears nine N-
glycosylation sites [57,58], of which two, Asn241 and Asn341,
are respectively located in the PAS region and the BDR. In
fact, no Fab binding to either native or deglycosylated HuBChE
was observed using a native-PAGE mobility shift assay (data
not shown), consistent with the sequence differences in these
regions in the two enzymes.
Crystal structure of Fab408 at 1.9 Å resolution and
implications for binding the BDR of EeAChE
The structure of Fab408, the first known peptidic ligand
targeting the BDR of an AChE, shows the canonical β-
sandwich Ig fold and an elbow angle of 151.6° between the
pseudo-dyad axes relating the variable (VH and VL) and
constant (CH and CL) domains of the two chains (Figure 3).
The combining site is formed by the six CDRs emerging from
the Fab variable domains (Figure 1 & Figure 3A). In the VL
domain, the side chains of CDR-L1 residues Asn28, Asp30 and
Tyr32 and of all CDR-L2 and CDR-L3 residues are oriented
Structure of Inhibitory Anti-AChE Antibodies
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towards the solvent, with CDR-L3 being stabilized by two ionic
interactions involving the His90 imidazole ring, the Thr93
carbonyl and the Thr97 hydroxyl. In the VH domain, Ser28
provides the only solvent-exposed side chain in CDR-H1 while
the neighboring Tyr27 and Phe29 are totally buried within the
molecule. The tip of CDR-H2 is bent inward. CDR-H3 consists
of a long, 17-residue loop largely exposed to the solvent,
except for residues Tyr110 and Phe111 at its base that
contribute to the tight assembly of the H and L chains.
In Fab408, all six CDRs display local pI values below 7.0
(Figure S1B in File S1). As a result, the ~1000 Å2 surface
defined by the CDRs is mostly populated by anionic side
chains (Figure 3B). This electronegative patch confers on the
Fab408 molecule a clear anisotropic distribution of surface
charges with a moderate dipole moment of 484 Debyes and a
vector oriented toward the H-chain N-terminus, opposite to the
CDRs. This is consistent with the Fab408 neutral pI value
(Figure 1; Table 1) and its interaction with the BDR of EeAChE,
which is remote by more than 100° from the axis linking PAS
residue Trp281 (homologous to mAChE Trp286) to active site
residue Ser202 (mAChE Ser203) and roughly aligns with the
dipole vector of the subunit (cf. below).
Figure 2.  Physical and functional characterization of the purified Fabs (typical experiments).  (A) MALDI-TOF mass
spectrometry profiles, showing both the di-charged and mono-charged entities. Note the satisfactory homogeneity in mass of the
latter. (B) Electrophoresis patterns obtained by SDS-PAGE in non-reducing conditions (12.5% PhastGel, left) and native-PAGE
(7.5% PhastGel, center) with migration from the cathode (top) toward the anode (bottom), and by isoelectric focusing (pI 3-9
PhastGel, right). The three Fabs are more homogenous in mass than in charge, a feature that likely result from variations in the C-
terminus generated by papaine cleavage of the CH chain; yet, all isoforms bind EeAChE equally, as verified by a native-PAGE
mobility shift assay (not shown). The neutral average pI of Fab408 and cationic average pIs of Fab403 and Fab410 are evident. (C)
Inhibition of native EeAChE (closed symbols, full lines) and N-deglycosylated EeAChE (open symbols, dashed lines) by the three
Fabs. The higher residual activity recorded at saturating concentration of Fab408, compared with Fab403 and Fab410, is evident.
Removal of the six N-linked glycan chains of EeAChE results in 6.5-fold higher affinity for Fab403 but unaltered residual activity at
saturating Fab403 concentration. Data points correspond to the average values of duplicates or mean values of triplicates. Non-
linear fitting of the data points used a sigmoidal equation. Mean values of the mass, pI, IC50 and residual activity of each Fab are
reported in Table 1.
doi: 10.1371/journal.pone.0077226.g002
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Figure 3.  Structure of Fab408 and homology models of Fab403 and Fab410.  Left: Overall views of (A) Fab408, with a light
blue L chain and yellow H chain; (B) Fab403, with a violet L chain and orange H chain; (C) Fab410, with a dark blue L chain and
salmon H chain, displayed with their N-terminal variable region on top and C-terminal constant region at bottom. CDR-L1, CDR-L2,
CDR-L3 are displayed in blue, light green, dark green and CDR-H1, CDR-H2, CDR-H3 in red, orange, purple. The extended CDR-
H3 in Fab408 is clearly visible. Center: Close-up views of the combining sites, displayed as molecular surfaces with the CDRs
colored as on the left panels and labeled. Differences in the sizes of the CDRs and the shapes of the combining surfaces (pocket in
Fab408 versus extended surfaces in Fab403 and Fab410) are evident. Right: Distribution of the electrostatic potentials mapped on
the Fab molecular surfaces at -3 kT/e (red) to +3 kT/e (blue) (same orientation as on the central panels). Note the electronegative
combining site in Fab408 versus the electropositive combining sites in Fab403 (centered around the L-chain CDRs) and Fab410
(centered around the H-chain CDRs).
doi: 10.1371/journal.pone.0077226.g003
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At the center of the Fab408 combining site, the interface
between the VH and VL domains forms a small pocket of 10-12
Å diameter lined by side chains from the protruding CDR-H2
and CDR-H3 and the shorter CDR-L3 (Figure 3CD). Solvent-
exposed CDR-H2 residues Ser54, Thr55, Arg57, CDR-H3
residues Thr103, Leu105, Glu107 and the CDR-L3 Thr93-
Thr94 pair are well positioned for interaction with the BDR
surface. It has been reported that 70% of an antibody contacts
with its antigen involve contributions of
Tyr>Asp>Asn>Ser>Glu>Trp side chains, while 15% of the
antigen contacts with the antibody are triggered by Arg side
chains [59,60]. On one side of the Fab408 pocket, the long and
flexible CDR-H3, which encompasses a Glu-Asp-Trp-Tyr
tetrapeptide (i.e. four of the six signature residues above
defined) and a net negative charge, appears as a suitable
candidate for interaction with the BDR of EeAChE. Yet, only
cooperative binding of two (or more) CDRs at the BDR,
perhaps with accommodation of a protruding surface motif
within the Fab central pocket, would fulfill the requirement for
an average antibody-antigen interfacial area of ~1700 Å2 [60].
In turn, the combined contribution of aromatic and charged side
chains appears consistent with the subnanomolar IC50 of the
complex (Table 1). A likely scenario would involve primary
contribution of a few major anchoring interactions along with
complementary contribution of several minor stabilizing
interactions [61].
Mutagenesis studies performed using chimeras of EeAChE
and rat AChE, which is not inhibited by the Elec mAbs, along
with site-specific substitutions, pointed to the EeAChE 15-
residue peptide Glu484-Arg498, which corresponds to the
mAChE Asp460-Gln474 and TcAChE Val453-Arg467 peptides
in the α(1)8,9-α(2)8,9 surface loop (Figure S2 in File S1), as a
binding site for Elec408 [33]. In this peptide, the Leu487-
Thr490 segment, which contains a consensus sequence for N-
glycosylation at Asn488, and the neighboring Glu493 residue
are largely conserved amongst AChE species and in HuBChE,
while the other 11 residues are more variable. Moreover,
Arg486 is unique to EeAChE amongst all AChE species
(although it is found in HuBChE) (Figure S2 in File S1), while
replacing either Leu491 or Glu494 by their respective Val and
Arg counterpart in rat AChE abolished EeAChE inhibition by
Elec408 [33]. However, should EeAChE residue Asn488 be
glycosylated, as are the corresponding residues in recombinant
mAChE and HuBChE and in natural TcAChE [15,58,62], it
would have to be located out of the Fab408 binding site, since
PNGase treatment of EeAChE does not alter the Fab408
binding and inhibition properties (cf. above).
In fact, at the tip of the long and flexible CDR-H3 of Fab408,
Glu107 is well positioned to form a salt bridge with the Arg486
guanidinium. Using this possible interaction as a pivotal
anchor, and keeping Asn488 away, a search for
complementary interactions between Fab408 and EeAChE
pointed to the polar Ser54-Thr55 residue pair at the tip of CDR-
H2, positioned close to CDR-H3 in the combining site, while
small side chains protruding from CDR-L3, opposite to CDR-H3
across the central pocket, are suitably positioned to confer
additional polar interactions with Arg494 (Figure 3D). However,
considering the limited amount of experimental constraints
available (in contrast to the situation for Fab403, cf. below),
modeling of a Fab408-EeAChE complex was not attempted.
Model of Fab403 and implications for binding the PAS
of EeAChE
In the model of Fab403, the side chains of several residues
in each of the six CDRs point towards the solvent (cf.
Experimental Procedures). Analysis of the Fab403 CDR
sequences reveals a distinctive repartition of theoretical pI
values: for CDR-H1, CDR-H3 and CDR-L2 these values are in
the 5.2-6.0 range while for CDR-H2, CDR-L1 and CDR-L3 they
are in the 8.0-8.5 range (Figure 1; Figure S1B in File S1). As a
result, the ~1600 Å2 combining site of Fab403 is mostly
populated by cationic side chains (Figure 3B). This
electropositive patch, combined with an uneven repartition of
negatively charged residues within the rest of the molecule,
confers on the Fab403 molecule a clear anisotropic distribution
of surface charges, with a marked dipole moment of 1270
Debyes (i.e., ~2.6-fold higher than that of Fab408) and a dipole
vector roughly aligned along L-chain strand β4 and oriented
toward the L-chain CDRs (Figure 3B). This observation is
consistent with the observed high pI value of Fab403 (Figure 2;
Table 1) and its interaction with the PAS of EeAChE [32], as
does the cationic Fas2 molecule, with its dipole vector oriented
towards the tips of the positively charged loops I and II [26,63].
The three cationic CDRs in Fab403 also encompass residues
suitable for promoting hydrophobic interaction, as found for
loops I and II of Fas2. However, the conformation of CDR-H2
does not reflect its sequence homology with Fas2 loop I (cf.
above), since a two residue shift along the backbone places
residues His54-Thr55, instead of Thr56-Thr57, at the tip of the
CDR-H2 loop to mimic Fas2 loop I residues Thr8-Thr9 (Figure
S3 in File S1). As a result, compared with the Arg9 side chain
that protrudes at the edge of Fas2 loop I, the Arg59 side chain
lies ~20 Å away at the base of CDR-H2 in a position likely to
promote distinctive interactions with the AChE PAS.
The conserved electrostatic properties of Fab403 and Fas2
correlate with functional similarities. Indeed, Elec/Fab403 and
Fas2 bind the PAS competitively with each other and with
several other PAS ligands, and both the Elec/Fab403- and
Fas2-EeAChE complexes display low residual activities (Table
1) [32]. These features denote comparable (but not identical,
as suggested by the slightly different residual activities)
capacities of the two peptidic ligands to cover a large surface
area in the PAS region, occlude the active site gorge entrance,
and prevent substrate access to the active center, despite the
100-fold difference in their respective Kd values. Analysis of
rat/EeAChE chimeras designed to map the binding site of
Fab403 at the EeAChE surface pointed to residue Ser75
(mAChE Leu76, TcAChE Gln74) in the long Ω loop (loop b3-
β3) on one side of the gorge entrance, and to residues Gln279
(mAChE His284, TcAChE Val277) and Leu282 (mAChE
His287, TcAChE Asn280) in the facing short Ω loop (loop
α3(6,7)-α4(6,7)) on the other side of the gorge entrance, as
most critical binding partners [33]. The corresponding mAChE
or TcAChE residues are involved in binding Fas2, propidium,
decamethonium, BW284C51, and ATCh [7,8,13,20,21,26].
Finally, deglycosylation of EeAChE enhanced the Fab403
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affinity by almost one order of magnitude (Figure 2D; Table 1),
suggesting that one or several N-glycan chains are proximal to
the combining site. Of the six consensus sites for N-
glycosylation in EeAChE, one, at Asn345 (mAChE Asn350,
TcAChE Ser343), is located in the PAS region. All together,
these features suggest that the formation and conformation of
the Fab403-EeAChE complex obey electrostatics, chemical
and steric constraints close to those dictating the formation and
conformation of the Fas2-AChE complex (cf. Introduction), and
represent suitable constraints to frame and validate a flexible
docking study (cf. Experimental Procedures, and below).
The only EeAChE form available in suitable amounts and
molecular homogeneity for structural studies is the covalent
tetramer enzymatically processed from the natural asymmetric
(A12) form (cf. Reference [S5] in File S1), whose high flexibility
hinders generation of well diffracting crystals and hence, high-
resolution description of an EeAChE subunit [55]. Therefore,
based on the high sequence conservation amongst AChE
species, we generated a homology model of the subunit.
Analysis of the electrostatic potentials at the molecular surface
of the EeAChE subunit evidenced a marked anisotropy of
charge distribution, associated with a dipole vector roughly
aligned with the gorge path and oriented opposite to the PAS,
as observed for other AChE species [26,63-65] (data not
shown). The permanent dipole moment, of 1555 Debyes, is
1.8-fold and 0.9-fold greater than those of mAChE and
TcAChE, of 883 and 1760 Debyes, respectively. Software-
assisted docking of the modeled Fab403 onto the modeled
EeAChE subunit led to seven ensembles of four energetically
best models of a complex, of which one was predominantly
found in the lowest HADDOCK scores. In this model, the dipole
vectors of the two partners are roughly aligned and the Fab403
H and L chains contribute 640 Å2 and 510 Å2, respectively, to
the buried interfacial surface area. The combining site of
Fab403 traps the long Ω loop in EeAChE encompassing Ser75,
with residues Tyr101-Trp103 in the very hydrophobic CDR-H3
being anchored central to the binding interface (Figure 4). In
contrast to Fas2 residues Arg27 and Met33 at the tip of loop II,
which occlude the entrance of the active center gorge [13,26],
Fab403 residues Tyr101 and Lys102 in the shorter CDR-H3
are shifted slightly outward so that gorge occlusion in the
Fab403 complex is not as tight as in the Fas2 complex, as
reflected in the slightly different residual activities (cf.
Introduction) (Figure 4B). Vicinal to these anchoring residues,
CDR-H1 residues Ser31-Trp33 and CDR-H2 residues Tyr52
and His54 contribute to the binding interface through
interactions with EeAChE residues flanking the PAS. At the
periphery of the binding interface, CDR-L1 residues Arg30 and
Tyr31 and CDR-L2 residues Asn52 and Leu53 provide
additional contact points through polar and non polar
interactions with EeAChE residues Gln279 and Leu282, while
CDR-L3 only moderately contributes to the binding interface.
Non-CDR residues Tyr48, Ser55 and Ala59 in the L chain also
significantly contribute to the binding interface. Finally, close
proximity of CDR-H2 with PAS residue Asn345 is largely
consistent with the greater affinity of Fab403 for deglycosyled
EeAChE, compared with native EeAChE.
To validate this docking procedure, we also docked the Fas2
molecule onto the mAChE structure and the EeAChE model
using a limited number of ambiguous interaction restraints (see
Experimental procedures). Two and three ensembles of
models were respectively obtained, from which the first and
second best solutions generated by HADDOCK matched the
reference Fas2-mAChE complex structure, with rmsd values in
the 0.6-1.1 Å range (data not shown). Relevance of the
modeled Fab403-EeAChE complex was further assessed by
comparison with the crystal structures of mAChE or TcAChE
complexes with the organic PAS ligands propidium [15] and
acetylcholine [7,8] and with the bifunctional ligands BW284C51
[21] and decamethonium [20], which bind EeAChE
competitively with Elec403 [32] (Figure 4C). In fact, steric
clashes were observed between each of the four bound ligands
and CDR-H3 residue Tyr101 and, occasionally, neighboring
Lys102 in bound Fab403, thereby consistent with the
competition data. Finally, the Tyr71Met mutation in the long Ω
loop of BfAChE (Figure S2 in File S1) associated with subtle
substitutions in the short Ω loop at positions that contribute to
the binding interface in the model, e.g. Leu282Ser and
Ser287Lys, are likely to contribute to absence of BfAChE
inhibition by Fab403 [32].
Model of Fab410 and implications for binding the PAS
of EeAChE and BfAChE
In the model of Fab410, the side chains of several residues
in each of the six CDRs point towards the solvent (cf.
Experimental Procedures). As observed for Fab403 (cf. above),
analysis of the Fab410 CDRs reveals a distinctive repartition of
theoretical pI values: for CDR-H1, CDR- H3 and CDR-L1 these
values are in the 4.0-5.2 range, while for CDR-H2 and CDR-L2
they are in the 8.7-11.0 range; only CDR-L3 has a theoretical
pI value close to neutrality (Figure 1; Figure S1B in File S1). As
a result, the ~1000 Å2 combining site of Fab410 is markedly
electropositive, and its dipole moment, of 892 Debyes (i.e., 1.8
greater and 1.4-fold smaller than those of Fab408 and Fab403,
respectively), is associated with a vector roughly aligned along
H-chain strand β4 and oriented toward the H-chain CDRs,
instead of the L-chain CDRs as found in Fab403 (Figure 3C).
This observation is consistent with the observed high pI value
of Fab410 (Table 1) and its binding at the EeAChE PAS
competitively with Fab403 and Fas2 binding [32]. In fact, the
highly electropositive CDR-H2 appears as a prime candidate to
provide the attractive energy and primary anchor point for
Fab410 at the rim of the gorge, while the protruding CDR-H3,
with the Tyr104-Tyr105-Asp106 residue triplet at its tip, is
suitably positioned to provide additional contact points at the
periphery of the PAS, thereby extending the interfacial surface
area and number of stabilizing interactions for high affinity
binding.
Experimental information that can help delineate the Fab410
binding site at the EeAChE surface points to i) absence of
binding competition between Fab410 and the smaller, organic
PAS ligands, ii) a residual activity of the Fab410-EeAChE
complex slightly higher than that of the Fab403-EeAChE
complex, iii) critical contribution of Ser75, but not Gln279 and
Leu282, to Fab410 binding (Figure S2 in File S1; cf. Figure
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Figure 4.  Docking model of the Fab403-EeAChE complex and structural comparisons.  (A) Overall views of (top left) the most
representative docking model of the Fab403-EeAChE complex and (top right) the buried interface at the EeAChE surface, oriented
90° from each other. The EeAChE subunit is displayed in yellow and the L and H chains of Fab403 in violet and orange,
respectively. The AChE catalytic residues are displayed in orange at the center of the subunit and the long Ω loop in brown at the
subunit surface / complex interface. The positions for Trp281 (Trp279/286 in TcAChE/mAChE), for Ser75, Gln279, and Leu282
whose substitution prevents Fab403 binding, and for Asn345 whose deglycosylation enhances Fab403 binding, are indicated (stars)
and labeled. The arrow points to the entry of the active site gorge. For comparison, shown are the overall views of (bottom left) the
crystal structure of the Fas2-mAChE complex (accession code, 1KU6) and (bottom right) the buried interface at the mAChE surface,
oriented 90° from each other. The mAChE subunit is displayed in yellow and Fas2 in green. On the right panels, the AChE surfaces
buried by the bound Fab403 L chain (590 Å2) and H chain (1000 Å2) and by Fas2 (1029 Å2) are colored accordingly to the ligands.
Bound Fab403, but not bound Fas2, almost completely covers the long Ω loop. The similar surface areas buried by the Fab H chain
and by Fas2 at the AChE PAS denote similar plugging of the gorge entry. (B) Close-up view (left) of the Fab403-EeAChE complex
interface viewed as in (a) and showing the key EeAChE and main Fab interacting side chains, and close-up overlay (right) of
Fab403 and Fas2 as bound to AChE, showing the distinct lengths of Fas2 loop I and Fab403 CDR-H1 and distinct positioning of
their side chains at the gorge entrance. Standard and underlined labels are for residues in the Fab403 H and L chains, respectively,
and italicized labels for EeAChE residues with encircled Ser75, Leu282, Gln279, and Asn345. (c) Close-up views of the Fab403-
EeAChE complex overlaid with BW284C51 (salmon inhibitor molecule; 1E3Q) and decamethonium (pink; 1ACL) as bound to
TcAChE, and with propidium (green; 1N5R) and ACh (blue; 2HA4) as bound to mAChE and its Ser203Ala mutant, respectively.
PAS residue Trp281 is displayed in yellow, oxyanion hole residue Trp85 in brown, and the catalytic triad residues in orange. Steric
clashes between residues in the Fab403 CDR-H1 (red) and CDR-H3 (magenta) and each of the four organic PAS ligands are
evident.
doi: 10.1371/journal.pone.0077226.g004
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4A), which together suggested that Fab410 binds only one side
of the gorge rim, opposite to Trp281 (mAChE Trp286, TcAChE
Trp279), and that none of its CDRs occludes the gorge
entrance [32,33]. Moreover, unaltered binding of Fab410 upon
deglycosylation of EeAChE, denotes Asn345 positioning out of
the Fab410 binding site (Figure 2; cf. Figure 4A). These
constraints preclude Fab410 binding to three quarters of the
EeAChE PAS region, yet they do not provide sufficient
information as to the binding position and orientation of Fab410
at the periphery of the gorge entrance. Therefore, modeling of
the Fab410-EeAChE complex was not attempted.
In contrast to Elec-403, Elec-410 inhibits BfAChE with a
lower affinity compared to EeAChE [32,34]. Apart from
unpredictable structural variations between the two AChE
species, this feature denotes differences in the interaction
networks at the two PAS regions. Comparison of the EeAChE
and BfAChE sequences in the PAS surroundings points to
Tyr71Met, Ser80Gln and Met90Gly substitutions, close to the
conserved Ser75 and on the solvent-exposed face of the long
Ω loop, and to a Ser287Lys substitution in the short Ω loop, as
likely candidates for dictating a less favorable complex
interface (Figure S2 in File S1). Moreover, of the five
consensus sites for N-glycosylation of BfAChE, three, at
Asn343 (corresponding to EeAChE Asn345), Asn453 (EeAChE
Glu484) and Asn457 (EeAChE Asn488), are located on each
side of the gorge entrance (Figure S1 in File S1). Presence of
glycan chains at all three positions, compared to only two on
EeAChE, would provide additional constraints onto Fab410
positioning in the PAS region of BfAChE.
In conclusion, comparative analysis of a crystal structure of
Fab408, which inhibits EeAChE by binding to the BDR, and of
models of its Fab403 and Fab410 congeners, which inhibit
EeAChE by binding the PAS, points to distinctive surface
topographies and anisotropic repartitions of charges of their
combining sites, consistent with their respective target sites at
the EeAChE surface and the distinctive residual activities of
their EeAChE complexes. A flexible docking model of the
Fab403-AChE complex, based on the available functional data
and validated through independent modeling of Fas2-AChE
complexes, pictures a likely mode of Fab403 binding,
reminiscent of that of the Fas2 toxin. This comprehensive study
documents the molecular peculiarities of Fab403 and Fab410,
as the largest peptidic ligands directed towards the PAS, and of
Fab408, as the first peptidic ligand directed toward the BDR.
The structure of Fab408 also provides a unique template for
the design of new, specific modulators of AChE, to be assayed
as therapeutic agents to treat neuromuscular, ophthalmic, or
cognitive disorders associated with cholinergic deficiencies
[66]. Further structural analysis of these “Elec” mAbs bound to
AChE should provide detailed picturing of the individual
molecular determinants at the AChE surface and mechanisms
involved into regulation of catalysis.
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